Timothy L. Main, a director at Quest Diagnostics Inc., recently reported a transaction involving the acquisition of shares in the company. This action, filed on October 23, 2026, is significant as it underscores Main's ongoing commitment to the medical laboratory services sector.
Main acquired 18 shares of Quest Diagnostics on October 21, 2026, at a price of $235.937 per share. Following this transaction, Main now holds a total of 22,478 shares directly. Additionally, Main has 5,000 shares held in trust, indicating a substantial investment in the company.
Background
Quest Diagnostics Inc. is a leading provider of diagnostic information services. The company is incorporated in Delaware and is known for its extensive range of medical laboratory services. Its operations are crucial in providing vital health information to patients and healthcare providers.
According to recent filings, Quest Diagnostics has been active in the market, with its latest Form 4 submission being on October 23, 2026, following a series of filings throughout the year.
What the Filing Says
The filing details that Main's acquisition of shares was made through a dividend reinvestment plan. The document notes, "Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6." This indicates that Main opted to report the transaction early on this Form 4.
Impact
This acquisition may have implications for other shareholders and potential investors in Quest Diagnostics. As a director, Main's investment decisions can influence shareholder confidence and market perception of the company's future performance.
What's Next
The filing does not specify what happens next regarding Main's holdings or any future transactions.